A Trial Comparing Adductor Canal Catheter and Intraarticular Catheter Following Primary Total Knee Arthroplasty
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02497911|
Recruitment Status : Unknown
Verified October 2015 by Jaime Baratta, Thomas Jefferson University.
Recruitment status was: Enrolling by invitation
First Posted : July 15, 2015
Last Update Posted : October 23, 2015
|Condition or disease||Intervention/treatment||Phase|
|Acute Pain Regional Anesthesia Morbidity||Procedure: Adductor Canal Catheter Procedure: Intraarticular Catheter Drug: Ropivicaine Drug: Bupivicaine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||November 2015|
Experimental: Adductor Canal Catheter
Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
Procedure: Adductor Canal Catheter
0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
Experimental: Intraarticular Catheter
Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
Procedure: Intraarticular Catheter
0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
- Post-operative pain [ Time Frame: immediately postoperative period to post-operative day # 2 ]postoperative pain as measured by Visual Analog Scale at rest and with movement
- Postoperative opioid consumption [ Time Frame: immediat postoperative period to postoperative day # 2 ]Opioid consumption within hospitalization
- Chronic post-surgical pain [ Time Frame: 6-8 weeks post-operative ]Assess post-surgical pain and function as measured by PainDetect and WOMAC questionnaires at 6-8 weeks post-operative compared to preoperative pain and function
- Participation in Physical therapy [ Time Frame: immediate postoperative period to postoperative day #2 ]Physical therapy benchmarks such as active and passive range of motion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02497911
|Principal Investigator:||Jaime L Baratta, MD||Sidney Kimmel Medical Center at Thomas Jefferson University Hospital|